Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.27

1.03 (1.90%)

, CLVS

Clovis

$98.02

5.77 (6.25%)

07:03
07/31/17
07/31
07:03
07/31/17
07:03

Bristol-Myers and Clovis to evaluate combination of Opdivo and Rubraca

Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS) announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and Clovis Oncology's poly, or ADP-ribose, polymerase, or PARP, inhibitor Rubraca in pivotal phase 3 clinical trials.First in advanced ovarian cancer: First-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Second in advanced triple-negative breast cancers, orTNBC: First-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency, or HRD. The collaboration will also include a Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer. The Opdivo + Rubraca combination in mCRPC will be conducted as an arm of a larger Bristol-Myers Squibb-sponsored study. The planned multi-arm clinical trials will be conducted in the U.S., Europe, and possibly additional countries. Clovis will be the study sponsor and conducting party for the ovarian cancer study and Bristol-Myers Squibb will be the study sponsor and conducting party for the breast and prostate cancer studies.

BMY

Bristol-Myers

$55.27

1.03 (1.90%)

CLVS

Clovis

$98.02

5.77 (6.25%)

  • 02

    Aug

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

BMY Bristol-Myers
$55.27

1.03 (1.90%)

06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/27/17
GSCO
07/27/17
NO CHANGE
Target $63
GSCO
Buy
Bristol-Myers could test $50 level following MYSTIC failure, says Goldman Sachs at Goldman Sachs
Goldman analyst Jami Rubin said Bristol-Myers (BMY) could test the $50 level following the failure of AstraZeneca's MYSTIC trial as confidence gets hit for Bristol's PD-L1+CTLA4 thesis in 1L NSCLC and for its own registration phase 3 trial, CM-227, with a potential interim readout not expected till later in the year. The analyst does not have any contribution from 1L NSCLC in his estimates and note Bristol's assets and trial are very different from MYSTIC. Rubin would view any sell off on the news as a buying opportunity ahead of CM-227 optionality and or potential M&A. The analyst rates Bristol a Buy with a $63 price target.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
CLVS Clovis
$98.02

5.77 (6.25%)

06/22/17
RHCO
06/22/17
NO CHANGE
RHCO
Clovis price target raised to $105 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Clovis based on his belief that the company's PARP inhiobitor, Rubraca, showed "striking efficacy in all three cohorts" of a study. The analyst thinks that the drug will be approved in second phase and later ovarian cancer. He keeps a Buy rating on the shares.
06/22/17
OPCO
06/22/17
INITIATION
OPCO
Perform
Clovis initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Clovis with a Perform rating.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.

TODAY'S FREE FLY STORIES

TMUS

T-Mobile

$60.30

0.28 (0.47%)

09:00
11/21/17
11/21
09:00
11/21/17
09:00
Upgrade
T-Mobile rating change  »

T-Mobile upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRL

Hormel Foods

$33.40

0.28 (0.85%)

08:59
11/21/17
11/21
08:59
11/21/17
08:59
Technical Analysis
Technical View: Hormel Foods trades up after earnings beat »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

SNSS

Sunesis

$2.87

0.01 (0.35%)

, ABBV

AbbVie

$93.60

-0.01 (-0.01%)

08:58
11/21/17
11/21
08:58
11/21/17
08:58
Initiation
Sunesis, AbbVie initiated  »

Oppenheimer says Sunesis…

SNSS

Sunesis

$2.87

0.01 (0.35%)

ABBV

AbbVie

$93.60

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$22.53

0.38 (1.72%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Technical Analysis
Technical View: DSW down sharply after earnings, outlook, miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.96

1.17 (1.70%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Recommendations
Agilent analyst commentary  »

Agilent price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

, BAC

Bank of America

$26.74

0.12 (0.45%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Options
Notable open interest changes for November 21st »

Monday's total…

GE

General Electric

$17.98

-0.23 (-1.26%)

BAC

Bank of America

$26.74

0.12 (0.45%)

BABA

Alibaba

$188.00

2.87 (1.55%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Hot Stocks
Breaking Hot Stocks news story on Stone Energy »

Stone Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NETS

Netshoes

08:53
11/21/17
11/21
08:53
11/21/17
08:53
Recommendations
Netshoes analyst commentary  »

Netshoes valuation overly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$53.50

0.5 (0.94%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AXGN

AxoGen

$24.30

0.7 (2.97%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
AxoGen analyst commentary  »

AxoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Campbell continues to expect Campbell Fresh to return to profitability this year »

Says back to normal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Recommendations
General Electric analyst commentary  »

Deutsche Bank cuts target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Eaton Vance reports AUM $382.4B for FY17 »

This represents an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:46
11/21/17
11/21
08:46
11/21/17
08:46
Earnings
Eaton Vance reports Q4 adjusted EPS 70c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MBI

MBIA

$8.95

-0.06 (-0.67%)

, GME

GameStop

$16.44

0.13 (0.80%)

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

MBI

MBIA

$8.95

-0.06 (-0.67%)

GME

GameStop

$16.44

0.13 (0.80%)

AAOI

Applied Optoelectronics

$43.48

-1.56 (-3.46%)

XLV

Health Care Select Sector SPDR

$80.90

-0.34 (-0.42%)

NUGT

Direxion Gold Miners Bull

$28.92

-0.88 (-2.95%)

OSTK

Overstock.com

$56.65

4.25 (8.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

08:45
11/21/17
11/21
08:45
11/21/17
08:45
General news
U.S. October Chicago Fed National Activity index rose 0.29 points to 0.65 »

U.S. October Chicago Fed…

SSY

SunLink Health Systems

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Hot Stocks
Breaking Hot Stocks news story on SunLink Health Systems »

Sunlink Health Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$81.46

1.24 (1.55%)

08:44
11/21/17
11/21
08:44
11/21/17
08:44
Recommendations
Lowe's analyst commentary  »

Lowe's quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Hot Stocks
Campbell Soup says expects to complete Pacific Foods acquisition by year-end »

Says saw lower seasonal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SHOP

Shopify

$108.56

3.67 (3.50%)

, FB

Facebook

$178.74

-0.26 (-0.15%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Shopify, Facebook analyst commentary  »

Shopify price target…

SHOP

Shopify

$108.56

3.67 (3.50%)

FB

Facebook

$178.74

-0.26 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

, RAD

Rite Aid

$1.56

-0.03 (-1.89%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Recommendations
Amazon.com, Rite Aid analyst commentary  »

Amazon pharmacy…

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

RAD

Rite Aid

$1.56

-0.03 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Hot Stocks
Stone Energy, Talos to become wholly-owned subsidiaries of new holding company »

Under the terms of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
11/21/17
11/21
08:40
11/21/17
08:40
General news
Breaking General news story  »

Week of 11/18 Redbook to…

VKTX

Viking Therapeutics

$2.77

-0.02 (-0.72%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Initiation
Viking Therapeutics initiated  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.